Breast Cancer and Mediastinal Hodgkin's Lymphomas: Multidisciplinary Discussion

Clin Breast Cancer. 2023 Oct;23(7):681-686. doi: 10.1016/j.clbc.2023.06.006. Epub 2023 Jun 20.

Abstract

Treatment for Hodgkin's lymphoma (HL) has evolved, with modern treatments combining less toxic chemotherapy and radiation, leading to improved long-term disease-free survival. However, there is a higher chance of second cancer, especially breast cancer, following effective HL treatment. The impact of reduced radiation doses and volumes, as well as the use of advanced irradiation techniques, on the risk of second malignancy is not clear. According to medical organizations, the history of chest irradiation is a relative contraindication to breast preservation therapy for women with initial breast cancer, leading to a paradigm of mastectomy. This article proposes a discussion between radiation oncologists and surgeons to review major trials and recent developments on the prevalence of breast cancer following HL therapy, the risk of contralateral cancer, the feasibility of breast conserving surgery (BCS), as well as breast reconstruction modalities.

Keywords: Breast cancer; Hodgkin's lymphoma; Prevention; Radiation therapy; Surgery.

Publication types

  • Review

MeSH terms

  • Breast
  • Breast Neoplasms* / epidemiology
  • Breast Neoplasms* / therapy
  • Female
  • Hodgkin Disease* / drug therapy
  • Hodgkin Disease* / therapy
  • Humans
  • Mastectomy
  • Neoplasms, Second Primary*